Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Asset / Drug

Tecentriq

Drug and asset intelligence for Tecentriq with 11 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 3
Catalysts: 8
Stage: NDA/BLA

Sponsor company

Mechanism of action

PD-L1 Inhibitor

Recent signals(3)

RegulatoryJuly 18, 2026

FDA Grants Priority Review for Tecentriq Supplement Application

The FDA has granted priority review for the supplemental application of Tecentriq (atezolizumab) submitted by Genentech.

RegulatoryJune 11, 2026

FDA Grants Priority Review for Roche’s Tecentriq in Stage III Colon Cancer

The FDA has accepted Roche's sBLA for Tecentriq plus chemotherapy in stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

June 11, 2026

FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer

The FDA has accepted Roche's sBLA for Tecentriq in combination with chemotherapy for stage III dMMR/MSI-H colon cancer, with a decision expected by October 9, 2026.

Upcoming milestones(1)

Priority Review

Roche — Tecentriq

Priority review accelerates competitive pressure in adjuvant IO colon cancer.

June 28, 2026 · NDA/BLA

Related catalysts(8)

Topline Data

Roche — Tecentriq

July 18, 2026 · N/A

Topline Data

Roche — Tecentriq

July 2, 2026 · N/A

Priority Review

Roche — Tecentriq

Priority review accelerates competitive pressure in adjuvant IO colon cancer.

June 28, 2026 · NDA/BLA

Topline Data

Roche — Tecentriq

June 22, 2026 · N/A

Topline Data

Roche — Tecentriq

June 18, 2026 · N/A

Topline Data

Roche — Tecentriq

June 18, 2026 · N/A

Topline Data

Roche — Tecentriq

June 11, 2026 · N/A

Topline Data

Roche — Tecentriq

June 11, 2026 · N/A

Indications

Stage III colon cancer →

Therapeutic areas

Immunotherapy →

Oncology · Colorectal Cancer →

Oncology · Immunotherapy →

Oncology · Mesothelioma →

Oncology · NSCLC →

Oncology · PD-L1 Inhibitor →

Oncology · Small Cell Lung Cancer →

PD-L1 Inhibitor →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.